Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
详细信息 查看全文
- 作者：Robert Z. Orlowski ; Arnon Nagler ; Pieter Sonneveld ; Joan Bladé ; Roman Hajek ; Andrew Spencer ; Tadeusz Robak ; Anna Dmoszynska ; Noemi Horvath ; Ivan Spicka ; Heather J. Sutherland ; Alexander N. Suvorov ; Liang Xiu ; Andrew Cakana ; Trilok Parekh and Jesú ; s F. San-Miguel
- 刊名：Cancer
- 出版年：2016
- 出版时间：July 1, 2016
- 年：2016
- 卷：122
- 期：13
- 页码：2050-2056
- 全文大小：353K
- ISSN：1097-0142
文摘
Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received one or more lines of therapy. Protocol-defined final survival data from that study are provided here.